Cognition Therapeutics
CGTX
36 hedge funds and large institutions have $10.4M invested in Cognition Therapeutics in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
3% more funds holding
Funds holding: 35 → 36 (+1)
0.38% less ownership
Funds ownership: 24.25% → 23.87% (-0.38%)
20% less capital invested
Capital invested by funds: $13M → $10.4M (-$2.57M)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Carlson Capital
Dallas,
Texas
|
+$70.5K |
| 2 |
SFG
Steward Financial Group
Colleyville,
Texas
|
+$64K |
| 3 |
State Street
Boston,
Massachusetts
|
+$32.1K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$28.9K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$10K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.42K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$2.66K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.12K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.1K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$791 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Mercer Global Advisors
Denver,
Colorado
| $23K | – | – | – |
|
27
Charles Schwab
San Francisco,
California
| $17.2K | – | – | – |
|
|
RCG
28
Rock Creek Group
Washington,
District of Columbia
| $14.7K | – | – | – |
|
29
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $8.45K | – | – | – |
|
30
Bank of America
Charlotte,
North Carolina
| $7.2K | +$7.83K | +5,000 | New |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| $5.13K | -$1.1K | -703 | -16% |
|
|
BCA
32
Bray Capital Advisors
Naples,
Florida
| $3.24K | – | – | – |
|
33
Wells Fargo
San Francisco,
California
| $184 | -$14 | -9 | -7% |
|
34
JP Morgan Chase
New York
| $36 | -$39 | -25 | -50% |
|
35
Fidelity Investments
Boston,
Massachusetts
| $1 | – | – | – |
|
|
36
UBS Group
Zurich,
Switzerland
| – | -$1.12K | -610 | Closed |
|
37
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$362 | -231 | -91% |
|
CGTX Hedge Fund Activity: Q3 2023 in Review
36 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Cognition Therapeutics (CGTX) for Q3 2023, worth a combined $10.4M — down 20% from $13M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CGTX positions and 1 closed out — a net gain of 1 holder — while 5 added to existing stakes and 7 trimmed.
The largest buyer was Carlson Capital, adding an estimated $70.5K. The largest seller was BlackRock, cutting an estimated $3.42K.
- 36 institutional investors held Cognition Therapeutics (CGTX) as of Q3 2023, up from 35 in Q2 2023.
- Funds reported $10.4M of Cognition Therapeutics stock for Q3 2023, down 20% quarter-over-quarter.
- 2 funds opened new Cognition Therapeutics positions in Q3 2023 and 1 closed out, a net change of +1 holder.
- The largest Cognition Therapeutics buyer in Q3 2023 was Carlson Capital, an estimated $70.5K added.
- The largest Cognition Therapeutics seller in Q3 2023 was BlackRock, an estimated $3.42K sold.
Based on aggregated 13F filings for Q3 2023.